Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EUK 189

Drug Profile

EUK 189

Alternative Names: EUK-189; Synthetic catalytic scavenger

Latest Information Update: 09 Jan 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteome Systems
  • Developer Tyrian Diagnostics
  • Class Organometallic compounds; Salicylates; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cognition disorders; Radiation-induced skin damage

Most Recent Events

  • 09 Jan 2009 Discontinued - Phase-I for Radiation-induced skin damage in USA (Topical)
  • 10 May 2007 Minerva Healthcare Inc. granted an option to license EUK 189 and other topical Eukarion compounds
  • 17 Nov 2006 Phase-I clinical trials in Radiation-induced skin damage in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top